Forbion — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
BiotechScotch Plains, US
NAVEEN MANU DARYANI(Executive Officer)STEPHEN BASIL THOMAS(Executive Officer, Director, Promoter)WILLIAM DALEY BONIFICIO(Executive Officer, Promoter)
BoardANDREW LEVIN(Director)
Board seatWouter Joustra· per SEC Form D · $100M raise · filed Sep 2024
Co-investorsRA Capital
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.
BiotechDeep TechCambridge, GB
David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in
Co-investorsNovartis Venture FundSV Health InvestorsDementia Discovery Fund
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Co-investorsAlta PartnersLongwood FundMission BiocapitalDolby Family VenturesService Provider Capital
Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells.
BiotechHealthtechMedical Devices
Co-investorsSofinnova PartnersBritish Patient CapitalGilde Healthcare
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.